ferric-carboxymaltose and omecamtiv-mecarbil

Over the last years, several trials offered new evidence on heart failure (HF) treatment.. For HF with reduced left ventricular ejection fraction, type 2 sodium-glucose cotransporter inhibitors, aside from sacubitril-valsartan, demonstrated extraordinary efficacy in ameliorating patients' prognosis. Some new molecules (eg vericiguat, omecamtiv mecarbil and ferric carboxymaltose) correct iron deficiency and have shown to be capable of furthering reducing the burden of HF hospitalisation. Finally, there is new evidence on the possible therapeutic approaches of HF patients with mid-range or preserved left ventricular ejection fraction.. This review aimed to revise the main novelties in the field of HF therapy and focus on how the daily clinical approach to patient treatment is changing.

Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotonic Agents; Drug Combinations; Ferric Compounds; Heart Failure; Heterocyclic Compounds, 2-Ring; Hospitalization; Humans; Iron Deficiencies; Maltose; Pyrimidines; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Urea; Valsartan; Vasodilator Agents; Ventricular Remodeling

Topics: Cardiovascular Agents; Evidence-Based Medicine; Ferric Compounds; Glycosides; Heart Failure, Systolic; Hospitalization; Humans; Maltose; Randomized Controlled Trials as Topic; Recovery of Function; Research Design; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Urea; Ventricular Function, Left